Guest guest Posted June 16, 2009 Report Share Posted June 16, 2009 This caught my eye...... seemingly on the one hand to recognise that(up to) 10% of patients currently taking statin medications could suffer from myalgias (muscle aches and pains), however they are considered benign..... (obviously the authors have not been amongst the 10%!!!) and then on they waffle looking for ways to continue treating people with statins, because as they say: this will probably become more common as greater numbers are prescribed high dose statin therapy.... blah blah...... they want research done into identifying patients at risk of developing mayopathies ---- no mention of withdrawing the drug - end of myopathy! Arghhhhhhhh ONCE AGAIN it is a case of you gotta take this drug so get used to the side effects - deal with it ----- IMHO! Narrative Review: Statin-Related Myopathyhttp://www.annals.org:80/cgi/content/abstract/150/12/858 Tisha R. Joy, MD, and Robert A. Hegele, MD 16 June 2009 | Volume 150 Issue 12 | Pages 858-868 Statin-related myopathy is a clinically important cause of statin intolerance and discontinuation. The spectrum of statin-related myopathy ranges from common but clinically benign myalgia to rare but life-threatening rhabdomyolysis. Observational studies suggest that myalgia can occur in up to 10% of persons prescribed statins, whereas rhabdomyolysis continues to be rare. The mechanisms of statin-related myopathy are unclear. Options for managing statin myopathy include statin switching, particularly to fluvastatin or low-dose rosuvastatin; nondaily dosing regimens; nonstatin alternatives, such as ezetimibe and bile acid–binding resins; and coenzyme Q10 supplementation. Few of these strategies have high-quality evidence supporting them. Because statin-related myopathy will probably become more common with greater numbers of persons starting high-dose statin therapy and the increasing stringency of low-density lipoprotein cholesterol level targets, research to better identify patients at risk for statin myopathy and to evaluate management strategies for statin-related myopathy is warranted. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 17, 2009 Report Share Posted June 17, 2009 , " Clare McHarris " <theclaremcharris wrote: > > .... (up to) 10% of patients currently taking statin medications could suffer from myalgias (muscle aches and pains), however they are considered benign..... You may be interested to know that approximately two years ago, the World Health Organization issued a report which, not surprisingly, went unremarked, unreported and then disappeared. The researchers claimed that what was being reported world-wide as an epidemic of ALS / Lou Gehrig's Disease, was quite possibly NOT ALS but extreme cases of Statin-induced myalgias, etc. Please keep in mind that there is no definitive diagnostic test for ALS. Rather, ALS is assumed when all other " known " factors are ruled out. > -- > > -- > > Narrative Review: Statin-Related Myopathy > http://www.annals.org:80/cgi/content/abstract/150/12/858 > Tisha R. Joy, MD, and Robert A. Hegele, MD > > 16 June 2009 | Volume 150 Issue 12 | Pages 858-868 > Statin-related myopathy is a clinically important cause of statin intolerance and discontinuation. The spectrum of statin-related myopathy ranges from common but clinically benign myalgia to rare but life-threatening rhabdomyolysis. Observational studies suggest that myalgia can occur in up to 10% of persons prescribed statins, whereas rhabdomyolysis continues to be rare. The mechanisms of statin-related myopathy are unclear. Options for managing statin myopathy include statin switching, particularly to fluvastatin or low-dose rosuvastatin; nondaily dosing regimens; nonstatin alternatives, such as ezetimibe and bile acid–binding resins; and coenzyme Q10 supplementation. Few of these strategies have high-quality evidence supporting them. Because statin-related myopathy will probably become more common with greater numbers of persons starting high-dose statin therapy and the increasing stringency of low-density lipoprotein cholesterol level targets, research to better identify patients at risk for statin myopathy and to evaluate management strategies for statin-related myopathy is warranted. > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 17, 2009 Report Share Posted June 17, 2009 Karin thanks for your email 10% is a low number....... VERY LOW in fact...... Those who have been affected by these drugs will tell you that medics per se sill believe very few are suffering bad effects...... Statins save very few if any lives..... cause multiple other disorders and cost gazillions of dollars...... Clare in Tasmania You may be interested to know that approximately two years ago, the World Health Organization issued a report which, not surprisingly, went unremarked, unreported and then disappeared. The researchers claimed that what was being reported world-wide as an epidemic of ALS / Lou Gehrig's Disease, was quite possibly NOT ALS but extreme cases of Statin-induced myalgias, etc. Please keep in mind that there is no definitive diagnostic test for ALS. Rather, ALS is assumed when all other " known " factors are ruled out. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 17, 2009 Report Share Posted June 17, 2009 Karen this article points to ALS type symptoms............... STATIN CAUSATION INTRODUCTIONIf Medwatch is the protective health "umbrella" in the United States for post-marketing ADRs, how is it that eight years after the official Medwatch reporting of my personal Lipitor-associated transient global amnesias to FDA, the Chief of Cardiology of a major university/teaching hospital can tell me recently during a symposium that he had never heard of any significant cognitive problems from statin drugs? He was lecturing a large group of medical personnel about statin drug use. Similarly, it was Ralph Edwards of the World Health Organization's Vigibase drug monitoring system who announced to the world "excess ALS associated with statin use worldwide, " while FDA stood silent. They apparently had missed it. http://www.spacedoc.net/medwatch_lipitor.html - "Karin Pine" You may be interested to know that approximately two years ago, the World Health Organization issued a report which, not surprisingly, went unremarked, unreported and then disappeared. The researchers claimed that what was being reported world-wide as an epidemic of ALS / Lou Gehrig's Disease, was quite possibly NOT ALS but extreme cases of Statin-induced myalgias, etc. Please keep in mind that there is no definitive diagnostic test for ALS. Rather, ALS is assumed when all other "known" factors are ruled out. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.